© 2019

Cancer Drug Delivery Systems Based on the Tumor Microenvironment

  • Yasuhiro Matsumura
  • David Tarin

Table of contents

  1. Front Matter
    Pages i-xi
  2. Cancer Pathophysiology

    1. Front Matter
      Pages 1-1
    2. Yasuhiro Matsumura
      Pages 23-40
    3. Kyoko Hida, Nako Maishi, Yasuhiro Hida
      Pages 41-56
  3. Antibody Drug Conjugates (ADC)

    1. Front Matter
      Pages 91-91
    2. Yoshikatsu Koga, Ryo Tsumura, Yasuhiro Matsumura
      Pages 125-154
    3. Yuki Abe, Kiyoshi Sugihara, Takashi Nakada, Javad Shahidi, Gilles J. A. Gallant, Takahiro Jikoh et al.
      Pages 155-174
  4. Hybrid Techniques of Active and Passive Targeting

    1. Front Matter
      Pages 175-175
    2. Nobuhiro Nishiyama
      Pages 177-186
    3. Kosuke Shimizu, Naoto Oku
      Pages 187-216
    4. Ikramy A. Khalil, Hiroto Hatakeyama, Takashi Nakamura, Hideyoshi Harashima
      Pages 217-251
  5. Cancer Stromal Targeting (CAST) Therapy and Diagnosis

    1. Front Matter
      Pages 253-253
    2. Yasuhiro Matsumura
      Pages 255-267
    3. Masahiro Yasunaga, Shino Manabe, Yasuhiro Matsumura
      Pages 269-288
    4. Atsushi B. Tsuji, Tsuneo Saga
      Pages 289-307
  6. The Current Status of Cancer Drug Delivery Systems and Future Directions

    1. Front Matter
      Pages 309-309
    2. Yasuhiro Matsumura, David Tarin
      Pages 311-319
  7. Back Matter
    Pages 321-325

About this book


This book proposes the importance of new systems of drug design and delivery based on cancer pathophysiology in addition to cancer molecular and cellular biology. The current studies based on molecular and cellular biology while ignoring pathophysiology and pharmacology may be leading the development of antitumor drugs in the wrong direction and wasting a lot of money. Although there have been numerous reports of genetic and phenotypic changes in tumors, a large body of pathological and clinical evidence supports the conclusion that there are no pivotal changes in tumor cells that distinguish them consistently and reliably from normal dividing cells. Unlike using antibiotics against bacterial infection, therefore, anticancer agents (ACAs) need to be delivered selectively to tumor tissues and should be kept there long enough to reproduce the concentrations they reach in the Petri dish, which is a closed space where the cytocidal effects of any anticancer agents (ACAs) including molecular targeting agents are very strong. In the body, however, administered ACAs are cleared with the passage of time. Furthermore, most human cancers possess abundant stroma that hinders the penetration of drugs into the tumor microenvironment. Therefore, to overcome these difficulties, novel drug delivery systems have been designed, such as nanoparticles and ACA conjugated antibodies to stromal components and to cancer cell surface antigens. These advances are described in this book after the first section, which describes core features of the pathophysiology of the cancer microenvironment, on which these new developments are based.


Anticancer Agents Cancer Biology Cancer Therapy Cancer pathphysiology Nanobiotechonology

Editors and affiliations

  • Yasuhiro Matsumura
    • 1
  • David Tarin
    • 2
  1. 1.Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial CenterNational Cancer CenterKashiwaJapan
  2. 2.Moores UCSD Cancer Center and Department of PathologyUniversity of California San DiegoLa JollaUSA

About the editors

Yasuhiro Matsumura, MD, PhD, Director, Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan

David Tarin, MD, PhD, FRCPath, Professor of Pathology, UC San Diego Moores Cancer Center, University of California, USA

Bibliographic information